NORMED, INC. – Trademark Portfolio
Entity Type: 03
NORMED, INC. holds 32 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 29 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 24 trademarks are registered and 1 is pending. Notable registered marks include HART, BLUTEC, NORMED, CETAFEN, and EXAPRIN. The owner is based in Seattle, WA.
4310 S 131st Place, Suite 160
Seattle, WA 98168
Showing of trademarks Trademarks
Trademark Classifications
NORMED, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does NORMED, INC. have?
NORMED, INC. has 32 U.S. trademarks filed with the USPTO. Of these, 24 registered, 1 pending, 5 abandoned, 2 cancelled.
What trademark classes does NORMED, INC. file in?
NORMED, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NORMED, INC.'s most well-known trademarks?
NORMED, INC.'s registered trademark portfolio includes well-known marks such as HART, BLUTEC, NORMED, CETAFEN, and EXAPRIN. These are among 24 currently registered trademarks in the portfolio.
What is NORMED, INC.'s trademark registration success rate?
NORMED, INC. has a 77% trademark registration rate, with 24 out of 31 resolved applications resulting in successful registration. Currently, 1 application is pending review.